Repros says FDA seeks more studies for testosterone drug

(Reuters) – Repros Therapeutics Inc said the U.S. health regulator sought additional studies of its testosterone replacement drug, Androxal, and recommended that a safety study of the drug be extended, delaying potential approval. Shares of the company fell 33 percent in premarket trading. Repros said the company’s marketing approval application would be delayed to the fourth quarter of 2014, if the results of the study have to be included. The company was earlier expecting to file the application in mid-2014. Analysts said the slight delay could be a positive. …

Rising drug resistance threatens global progress against TB

A tuberculosis patient listens as a doctor shows the condition of his lungs at the Indonesian Union Against Tuberculosis clinic in JakartaBy Kate Kelland LONDON (Reuters) – The number of people infected with tuberculosis (TB) or dying from it fell in 2012, but global progress on controlling the contagious lung disease is at risk from growing drug resistance. In its annual TB report, the Geneva-based World Health Organization (WHO) said the world is on track to meet U.N. goals for 2015 of reversing TB incidence and cutting the death rate by 50 percent compared to 1990. …

1 34 35 36 37 38 113